Printer Friendly

SYNERGEN BEGINS OPERATIONS IN JAPAN

 BOULDER, Colo., Dec. 2 ~PRNewswire~ -- Synergen Inc. (NASDAQ: SYGN) announced today the appointment of Mary E. Bareilles, M.D., as director of corporate clinical research and vice president of clinical research for Synergen's new operations in Japan. In this newly created position, Bareilles will be responsible for helping to form and implement Synergen's clinical development strategy in Japan. Bareilles is Synergen's first employee in Japan.
 "Dr. Bareilles brings us extensive drug development and regulatory experience in the Japanese drug development environment. As we begin clinical development in Japan, we are very pleased to have attracted someone of Dr. Bareilles' excellent reputation and experience," said Michael A. Catalano, M.D., vice president of clinical research at Synergen.
 Synergen will start Phase I clinical trials in Japan in the near future to study ANTRIL(TM), the company's leading investigational product, for use in patients with sepsis. Hiring Bareilles and beginning this trial are the first steps in building Synergen's operations in Japan.
 Bareilles joined Synergen from Upjohn Pharmaceuticals Ltd. in Japan where for the last three years she held the position of director, clinical development and medical affairs. Prior to her tenure at Upjohn, she held several medical affairs positions at Abbott Laboratories, Sterling Drugs Inc. and Ciba-Geigy in Japan. A graduate of Keio University Medical School in Tokyo, Bareilles also conducted research at Kobe University School of Medicine.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted toward products for inflammatory diseases, tissue repair and neurological diseases. The company is headquartered in Boulder with manufacturing operations in Boulder and Delaware, and European operations in The Hague.
 -0- 12~2~92
 ~CONTACT: Paul Laland (Media), 303-541-1325 or Debra Bannister (Financial), 303-938-6242, both of Synergen~
 (SYGN)


CO: Synergen Inc. ST: Colorado IN: MTC SU:

MC -- DV003 -- 2743 12~02~92 08:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1992
Words:311
Previous Article:GASOLINE PRICES DECREASE 3.3 CENTS PER GALLON SINCE NOVEMBER
Next Article:CREME DE LA CREME LIST OF BANKING
Topics:


Related Articles
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
SYNERGEN APPOINTS DIRECTOR OF QUALITY
SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
SYNERGEN AND SELECTIDE ANNOUNCE COLLABORATION
SYNERGEN REPORTS 1992 FINANCIAL RESULTS
NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE
SYNTEX-SYNERGEN JOINT VENTURE ALS STUDY UNDERWAY
SYNERGEN FILES EUROPEAN MARKETING APPLICATION FOR ANTRIL IN SEVERE SEPSIS
SYNERGEN BEGINS PHASE I CLINICAL TRIAL WITH NOVEL PROTEIN FOR INFLAMMATORY DISEASES
SYNERGEN REPORTS FIRST QUARTER FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters